Lymphocytosis as a predictor of poor response to treatment of hepatitis C;Lymphocytose comme un facteur prédictif de mauvaise réponse au traitement de l'hépatite C

Clinics and Research in Hepatology and Gastroenterology

Volumn 35, Issue 1, 2011, Pages 34-40

  Martinez Camacho, A ^a   Khaoustov, V I ^a   Adam, E ^a   Lewis, D E ^a   Tavakoli Tabasi, S ^a   Yoffe, B ^a  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON;

ADULT; AFRICAN AMERICAN; ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; EUROPEAN AMERICAN; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; HYPERSPLENISM; LEUKOPENIA; LYMPHOCYTE; LYMPHOCYTOSIS; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; NEUTROPHIL; PREDICTOR VARIABLE; RETROSPECTIVE STUDY;

CROSS-SECTIONAL STUDIES; FEMALE; HEPATITIS C; HUMANS; LYMPHOCYTOSIS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT FAILURE;

EID: 79956030070     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.gcb.2010.08.008     Document Type: Article

References (30)

1. Chen S.L., Morgan T.R. The natural history of hepatitis C virus infection. Int J Med Sci 2006, 3:47-52.
2. World Health Organization. Hepatitis C: fact sheet no. 164. http://www.who.int/mediacentre/factsheets/fs164/en.
3. Alter M.J., Kruszon-Moran D., Nainan O.V., et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999, 341:556-562.
4. Armstrong G.L., Wasley A., Simard E.P., et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006, 144:705-714.
5. US Department of Health and Human Services. 2005 Annual report of the U. S. OPTN and SRTR: Transplant Data 1995-2004 Rockville, MD: Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation.
6. Hoofnagle J.H., Seeff L.B. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med 2006, 355:2444-2451.
7. Hadziyannis S.J., Sette H., Morgan T.R., et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004, 1(40):346-355.
8. Fried M.W., Shiffman M.L., Reddy K.R., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975-982.
9. Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatology 1997, 26:112S-121S.
10. Fried M.W. Side effects of therapy of hepatitis C and their management. Hepatology 2002, 36:237S-244S.
11. Kau A., Vermehren J., Sarrazin C. Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol 2008, 49:634-651.
12. Conjeevaram H.S., Fried M.W., Jeffers L.J., et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006, 131:470-477.
13. Patton H.M., Patel K., Behling C., et al. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol 2004, 40:484-490.
14. Dai C.Y., Huang J.F., Hsieh M.Y., et al. Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients. J Hepatol 2009, 50(4):712-718.
15. Fujita N., Sugimoto R., Urawa N., et al. Hepatic iron accumulation is associated with disease progression and resistance to interferon/ribavirin combination therapy in chronic hepatitis C. J Gastroenterol Hepatol 2007, 22:1886-1893.
16. Muir A.J., Bornstein J.D., Killenberg P.G. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-hispanic whites. N Engl J Med 2004, 350:2265-2271.
17. Ghany M.G., Strader D.B., Thomas D.L., et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009, 49:1335-1374.
18. Davis G.L., Wong J.B., McHutchison J.G., et al. Early virologic response to treatment with Peginterferon alpha-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003, 38:645-652.
19. Mangia A., Minerva N., Bacca D., et al. Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial. Hepatology 2008, 47:43-50.
20. Shirakawa H., Matsumoto A., Joshita S., et al. Pretreatment prediction of virologic response peginterferon plus ribavirin therapy in chronic hepatitis C patient using viral and host factors. Hepatology 2008, 48:1753-1760.
21. Hsieh M.M., Everhart J.E., Byrd-Holt D.D., et al. Prevalence of neutropenia in the U.S. population: age, sex, smoking status, and ethnic differences. Ann Intern Med. 2007, 146:486-492.
22. McHutchison J.G., Shad J.A., Gordon S.C., et al. Predicting response to initial therapy with interferon plus ribavirin in chronic hepatitis C using serum HCV RNA results during therapy. J Viral Hepat 2001, 8:414-420.
23. Lewis D.E., Ng Tang D.S., Wang X., et al. Costimulatory pathways mediate monocyte-dependent lymphocyte apoptosis in HIV. Clin Immunol 1999, 90:302-312.
24. Thiagarajan P., Tait J.F. Binding of annexin V/placental anticoagulant protein I to platelets. Evidence for phosphatidylserine exposure in the procoagulant response of activated platelets. J Biol Chem 1990, 65:17420-17423.
25. Sugimoto K., Stadanlick J., Ikeda F., et al. Influence of ethnicity in the outcome of hepatitis C virus infection and cellular immune response. Hepatology 2003, 37:590-599.
26. Chen L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 2004, 4:336-347.
27. Golden-Mason L., Klarquist J., Wahed A.S., et al. Cutting Edge: Programmed death-1 expression is increased on immunocytes in chronic hepatitis C virus and predicts failure of response to antiviral therapy: race-dependent differences. J Immunol 2008, 180:3637-3641.
28. Pillai V., Lee W.M., Thiele D.L., et al. Clinical responders to antiviral therapy of chronic HCV infection show elevated antiviral CD4+ and CD8+ T-cell responses. J Viral Hepat 2007, 14:318-329.
29. Aberle J.H., Perstinger G., Weseslindtner L., et al. CD4+ T cell responses in patients with chronic hepatitis C undergoing peginterferon/ribavirin therapy correlates with faster, but not sustained, viral clearance. J Infect Dis 2007, 195:1315-1319.
30. Iken K., Huang L., Bekele H., et al. Apoptosis of activated CD4+ and CD8+ T cells is enhanced by co-culture with hepatocytes expressing hepatitis C virus (HCV) structural proteins through FasL induction. Virology 2006, 346:363-372.